[Ed. Note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.
There is a large number of names that I will be adding to the watch list this week. Since we are entering March soon, we want to start to research names in April and May so that we are ready to pounce!
As we enter small cap earnings season, be sure to double check your company’s earnings date! You can do so on a site like Earnings whispers.
Just a reminder, charts and targets are updated every Monday morning!
New Catalyst Swing names (1 – 4 week holds) I am watching…
Selecta Biosciences (SELB)
Catalyst Dates: Phase 2 data in early April
Buy Zone: $8.50 to $9.50
Profit Zone: $11.50 or higher
Stop Zone: $8.00 or below
Viking Therapeutics (VKTX)
Catalyst Dates: Phase 2 data for fatty liver disease due out in the 2nd quarter.
Buy Zone: $6.00 to $6.50
Profit Zone: $7.50 or higher
Stop Zone: $5.50 or below
Seattle Genetics (SGEN)
Catalyst Dates: FDA approval date of May 1
Buy Zone: $53.00 to $56.00
Profit Zone: $60.00 or higher
Stop Zone: $51.50 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $30.00 to $32.00
Profit Zone: $36.00 or higher
Stop Zone: $29.50 or below
Aimmune Therapeutics (AIMT)
Catalyst Dates: Phase 3 data at a conference March 2nd-5th (data already out, faster play)
Buy Zone: $32.00 to $33.00
Profit Zone: $35.50 or higher
Stop Zone: $31.50 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
Rigel Pharmaceuticals (RIGL)
Catalyst Dates: FDA approval date of April 17th for immune thrombocytopenic purpura
Buy Zone: $3.50 to $3.90
Profit Zone: $4.50 or higher
Stop Zone: $3.40 or below
Clovis Oncology (CLVS)
Catalyst Dates: FDA approval date of April 6th for ovarian cancer
Buy Zone: $52.00 to $55.00
Profit Zone: $60.00 or higher
Stop Zone: $49.00 or below
Savara (SVRA)
Catalyst Dates: Phase 2 heart failure data due on March 11th
Buy Zone: $11.75 to $12.50
Profit Zone: $14.00 or higher
Stop Zone: $11.00 or below
Ultragenyx Pharmaceuticals (RARE)
Catalyst Dates: FDA approval date of April 17th for X-linked Hypophosphatemia
Buy Zone: $44.00 to $47.00
Profit Zone: $55.00 or higher
Stop Zone: $41.00 or below
Progenics (PGNX)
Catalyst Dates: FDA Approval date of April 30th
Buy Zone: $5.50 to $6.00
Profit Zone: $7.00 or higher
Stop Zone: $5.10 or below
CorMedix (CRMD)
Catalyst Dates: Phase 3 interim analysis due out in the second quarter. Likely a buy after their earnings call in March.
Buy Zone: $.30 to $.40
Profit Zone: $.70 or higher
Stop Zone: $.25 or below
EDAP Tms (EDAP)
Catalyst Dates: FDA medical device approval for prostate cancer likely late 1Q
Buy Zone: $2.40 to $2.70
Profit Zone: $3.40 or higher
Stop Zone: $2.20 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.50 to $6.00
Profit Zone: $8.00 or higher
Stop Zone: $5.20 or below
Cidara Therapeutics (CDTX)
Catalyst Dates: Phase 2 Candidemia data due in the 1Q (likely sometime in March)
Buy Zone: $6.00 to $6.50
Profit Zone: $8.40 or higher
Stop Zone: $5.75 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2b initial biopsy data due late First Quarter.
Buy Zone: $1.95 to $2.15
Profit Zone: $2.40 or higher
Stop Zone: $1.75 or below
